<DOC>
	<DOCNO>NCT00840957</DOCNO>
	<brief_summary>Infliximab chimeric monoclonal antibody direct towards Tumor Necrosis Factor -alpha largely use inflammatory disease rheumatoid arthritis ( RA ) . A relationship dose clinical outcome show population RA patient interindividual variability relationship . At individual level , dose-effet relationship separate dose-concentration ( pharmacokinetic PK ) concentration-effet ( pharmacokinetic-pharmacodynamic PK-PD ) relationship . Serum trough concentration infliximab show variable patient receive treatment regimen . This PK variability may explain several factor ( e.g . genetic immunological factor ) . The concentration-effect relationship may also variable source variability need study well . To date detail infliximab PK analysis publish . The source variability dose-effect relationship need characterize optimize infliximab dose regimen patient . The FAKIR study multicenter prospective observational study focus patient treat infliximab . Its aim : 1. characterize PK PK-PD variability infliximab RA , use clinical criterion biomarkers , assessed time ; 2. study influence polymorphism FCGRT ( gene encode FcRn ) PK variability infliximab ; study influence polymorphism FCGR3A ( gene encode Fc gamma RIIIa ) PK-PD variability infliximab ; study influence antibody toward infliximab PK PK-PD variability infliximab .</brief_summary>
	<brief_title>Pharmaco Kinetic Variability Infliximab Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Rheumatoid arthritis accord ACR criterion Patient already receive infliximab 14 week No modification dose regimen infliximab since last infusion No modification disease modify anti rheumatic drug since last 4 week Surgery schedule duration study Pregnancy infection , malignancy , immune reaction infliximab demyelinating disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>